Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.71 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.71 |
| ▸ | BRAF | P15056 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15671934 | 1.00 | MAP2K1 (0.71) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL31078040 | 1.00 | MAP2K1 (0.71) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL4860874 | 0.88 | MAP2K1 (0.73) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL4854513 | 0.88 | MAP2K1 (0.73) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL24353542 | 0.87 | MAP2K1 (0.55) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL2022966 | 0.86 | MAP2K1 (0.74) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL2024960 | 0.86 | MAP2K1 (0.74) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL2024962 | 0.86 | MAP2K1 (0.74) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| Hydrochloric Acid SCHEMBL2024629 | 0.85 | MAP2K1 (0.72) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| Hydrochloric Acid SCHEMBL2024627 | 0.85 | MAP2K1 (0.72) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-4119552-A1 | REGULATING CHIMERIC ANTIGEN RECEPTORS | Dana-Farber Cancer Institute, Inc. (US) | 2023-01-18 | — | — | EP | disclosed |
| US-11311609-B2 | Regulating chimeric antigen receptors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | MAP2K1 2536/4885MAP2K2 1652/4885BRAF 913/4885 |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | MAP2K1 2820/4885MAP2K2 2288/4885BRAF 2604/4885 |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | MAP2K1 2820/4885MAP2K2 2288/4885BRAF 2604/4885 |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | MAP2K1 2536/4885MAP2K2 1652/4885BRAF 913/4885 |
| US-11311609-B2 | Regulating chimeric antigen receptors | NFATC1, TNFRSF9, IL2RA | MAP2K1 3937/4885MAP2K2 4177/4885BRAF 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.